AMERISOURCEBERGEN CORP shareholders Q3 2023

AMERISOURCEBERGEN CORP's ticker is ABC and the CUSIP is 03073E105. A total of 957 filers reported holding AMERISOURCEBERGEN CORP in Q3 2023. The put-call ratio across all filers is 1.30 and the average weighting 0.2%.

AMERISOURCEBERGEN CORP shareholders Q3 2023
NameSharesValueWeighting ↓
HF Advisory Group, LLC 7,394$1,337,4020.99%
Unigestion Holding SA 86,924$15,894,9230.98%
BENEDICT FINANCIAL ADVISORS INC 17,900$3,221,4230.93%
FIRST FOUNDATION ADVISORS 110,316$19,853,5500.93%
GUYASUTA INVESTMENT ADVISORS INC 66,508$11,969,4450.93%
Pacer Advisors, Inc. 1,321,905$237,903,2430.91%
LEUTHOLD GROUP, LLC 35,503$6,389,4750.90%
OmniStar Financial Group, Inc. 4,130$747,4540.89%
FERGUSON WELLMAN CAPITAL MANAGEMENT, INC 198,490$35,722,2450.88%
Ardevora Asset Management LLP 97,992$17,6360.87%
Leeward Investments, LLC - MA 94,079$16,931,3980.86%
TriaGen Wealth Management LLC 9,394$1,690,6380.86%
BURNEY CO/ 98,623$17,749,1440.83%
Westover Capital Advisors, LLC 12,553$2,259,1630.82%
Leith Wheeler Investment Counsel Ltd. 34,260$6,165,7700.82%
MQS Management LLC 7,419$1,335,1970.81%
Peterson Financial Group, Inc. 6,724$1,210,1880.81%
Chesley Taft & Associates LLC 67,633$12,171,9110.79%
VAUGHAN NELSON INVESTMENT MANAGEMENT, L.P. 382,602$68,8560.78%
Wolf Group Capital Advisors 8,986$1,617,2100.76%
About AMERISOURCEBERGEN CORP

AmerisourceBergen Corp is a pharmaceutical services company that provides drug distribution and related services to healthcare providers and pharmaceutical manufacturers. The company operates in two segments: Pharmaceutical Distribution Services and Other.

The Pharmaceutical Distribution Services segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide range of healthcare providers, including hospitals, clinics, and retail pharmacies. The Other segment provides consulting services, specialty transportation and logistics services, and other services to pharmaceutical manufacturers.

AmerisourceBergen Corp has a strong financial position, with a market capitalization of over $20 billion and a debt-to-equity ratio of 1.3. The company has a solid track record of revenue growth, with revenue increasing from $135 billion in 2016 to $189 billion in 2020.

The company's management team is led by Chairman of the Board Steven H. Collis and CEO and President James F. Cleary Jr. Both executives have extensive experience in the pharmaceutical industry and have been with the company for over 20 years.

In conclusion, AmerisourceBergen Corp is a well-established pharmaceutical services company with a strong financial position and experienced management team. The company's focus on providing drug distribution and related services to healthcare providers and pharmaceutical manufacturers has resulted in consistent revenue growth over the years. Investors looking for exposure to the pharmaceutical industry may want to consider adding AmerisourceBergen Corp to their portfolio.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists AMERISOURCEBERGEN CORP's shareholders in Q3 2023. To view AMERISOURCEBERGEN CORP's shareholder history, click here.